MORRISTOWN, N.J., Dec. 12, 2019 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical stage company developing technology to address injurious inflammation while protecting immune function and vital organs in diseases driven by inflammation and infection, announces publication of new research findings with recombinant human plasma gelsolin in influenza. The research demonstrates that recombinant human plasma gelsolin therapy dramatically improves survival in a highly lethal influenza animal model.

Access Research Publication Here

Findings Indicate That Plasma Gelsolin Supplementation Can Improve Influenza Outcomes

Seasonal influenza continues to be a cause of substantial morbidity and mortality. The US Center for Disease Control and Prevention (CDC) documented that seasonal influenza was responsible for close to 57,000 deaths during the 2018-2019 season. There is also concern that new strains could cause high death rates similar to past pandemics.

Studies conducted in collaboration with investigators at the Harvard T.H. Chan School of Public Health demonstrated clinical improvement in mice infected with lethal doses of influenza when administering gelsolin after a clinically relevant delay. The current FDA-approved antivirals target the flu virus, but do not address the severe later stage morbidity and mortality that that are the focus of plasma gelsolin (rhu-pGSN) therapy. Currently, resistance is also developing against the antivirals, which is why host-directed therapies are increasingly being sought for development.

Susan Levinson, PhD, Chief Executive Officer of BioAegis Therapeutics stated, “We’ve previously studied plasma gelsolin against multiple types of drug-sensitive and drug-resistant bacteria and this new data has demonstrated efficacy in influenza, a key viral pandemic threat. Each time we extend our studies with plasma gelsolin, we become even more persuaded of its potential to address serious medical needs where current therapy fails.”

Read the full press release here.


MORRISTOWN, N.J., Oct. 22, 2019 (BIOAEGIS THERAPEUTICS) — BioAegis Therapeutics was recently recognized by PitchBook as the most valuable venture-backed company in New Jersey led by a female entrepreneur. PitchBook is a financial data and software company that provides transparency to capital markets to help professionals discover and execute opportunities. BioAegis Therapeutics’ accolade was based on 2019 PitchBook data. Dr. Susan Levinson co-founded BioAegis in 2011 and has been its CEO since its inception.

Read the full press release here: PitchBook


MORRISTOWN, NJ, (August 22, 2019) BioAegis Therapeutics, Inc., a clinical stage company developing technology to control inflammation while protecting immune function and vital organs in diseases driven by inflammation and infection, announces publication of research results in the Journal of Infectious Diseases demonstrating that recombinant human plasma gelsolin therapy dramatically improves survival in a multidrug-resistant pneumonia animal model.   Furthermore, it works synergistically with previously ineffective antibiotics, making them work again.

Read the full press release here:  JID Publication Final 8-22-2019


MORRISTOWN, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc. announced the major findings from its Phase 1b/2a study of Recombinant Human Plasma Gelsolin for patients requiring hospitalization because of Community-Acquired Pneumonia.
This blinded placebo-controlled trial was a dose-escalation study with four cohorts of 8 patients randomized 3:1 to recombinant gelsolin versus placebo. The highest-dose cohort receive 3 consecutive daily doses of 24 milligrams per kilogram of body weight. As anticipated, no serious or drug-related adverse events were reported in what were the highest doses ever administered to patients. Furthermore, analysis of the pharmacokinetics demonstrated that the product half-life exceeded 12 to 16 hours which supports once-daily dosing.

See the full release here: 2019 08 06 Phase 1b 2a Results


MORRISTOWN, NJ, (BIOAEGIS THERAPEUTICS) April 30, 2019 BioAegis Therapeutics Inc., a privately held biotechnology company commercializing recombinant human plasma gelsolin (pGSN) announced today that the United States Patent Office has issued a patent for the Use of Plasma Gelsolin to Diagnose and Treat Renal Failure.

Read the full press release here: Renal Patent 2019